Resveratrol vs Quercetin: Polyphenol Showdown

Resveratrol

Resveratrol was originally proposed to activate SIRT1 (sirtuin 1) directly, mimicking caloric restriction. David Sinclair's landmark 2003 Nature paper triggered massive research interest and spawned a wave of nutraceutical products. However, subsequent work (notably Pfizer/GlaxoSmithKline research) cast doubt on whether resveratrol directly activates SIRT1 or whether the original assay was confounded. Current understanding suggests resveratrol's effects are indirect — it activates AMPK, inhibits mTOR, modulates NF-κB inflammation pathways, and affects mitochondrial function, but the direct SIRT1 mechanism is contested.

Quercetin

Quercetin functions as a PI3K/Akt pathway inhibitor and Bcl-2/Bcl-xL pro-survival signalling blocker. This combination is the basis for its senolytic activity — senescent cells upregulate these survival pathways to resist apoptosis, and quercetin disrupts this protection. The Mayo Clinic's James Kirkland has published multiple studies showing quercetin (combined with dasatinib, a tyrosine kinase inhibitor) clears senescent cells from human adipose tissue and reduces senescent cell burden. Quercetin also has anti-inflammatory, antioxidant, and anti-histamine properties.

Resveratrol

Resveratrol has notoriously poor oral bioavailability — rapidly metabolised in the gut and liver (first-pass effect), with <1% of dietary resveratrol reaching systemic circulation intact. High-dose supplements (250–1000 mg/day) aim to saturate this metabolism, and some formulations use liposomal, nanoparticle, or pterostilbene (a resveratrol analogue) delivery to improve uptake. Pterostilbene has approximately 4× better oral bioavailability than resveratrol due to methyl group substitutions reducing metabolic degradation.

Quercetin

Quercetin's bioavailability is similarly limited — oral quercetin aglycone achieves 20–50% absorption depending on formulation, with food matrix substantially affecting uptake. Quercetin phytosome (complexed with sunflower lecithin) improves absorption by ~20-fold in some formulations. In the senolytic protocol (D+Q: dasatinib 100 mg + quercetin 1000 mg), the intermittent dosing strategy (3 days on, ~4 weeks off) is designed to periodically reach sufficient tissue concentrations for senolytic activity rather than relying on consistent daily dosing.

Resveratrol

Human clinical trials on resveratrol have been largely disappointing relative to the animal and in-vitro hype. Multiple RCTs have failed to show meaningful effects on cardiovascular biomarkers, cognitive function, or metabolic endpoints in healthy adults. A notable 2015 trial by Timmers et al. found modest improvements in metabolic syndrome parameters, but effect sizes were small. The most consistent human finding is modest anti-inflammatory effects. No RCT has demonstrated meaningful lifespan-relevant outcomes in humans.

Quercetin

Quercetin's human evidence, while thin, is more directionally promising in the context of senolytics. A 2019 Mayo Clinic pilot study (n=14) in patients with idiopathic pulmonary fibrosis found D+Q reduced senescent cell markers in blood and skin. A 2020 study in diabetic kidney disease found reductions in senescent cell burden. These are small, early studies — but the mechanistic specificity (targeting a defined aging hallmark) gives quercetin's evidence a more focused scientific narrative than resveratrol's.

Resveratrol

Resveratrol is commonly stacked with NMN/NAD+ precursors (David Sinclair publicly takes both), with the rationale that SIRT1 activation requires NAD+ as a cofactor — making NAD+ and SIRT1-activating compounds potentially synergistic. Whether this synergy is real in humans is unproven. It is also sometimes combined with pterostilbene as a more bioavailable analogue and with quercetin in broader polyphenol stacks.

Quercetin

Quercetin's most important combination is with dasatinib (D+Q senolytic protocol), which appears to have superior senolytic potency than either agent alone. Quercetin is also combined with fisetin (another flavonoid senolytic), forming part of multi-senolytic protocols used in ongoing clinical trials. The Buck Institute and Mayo Clinic are investigating various senolytic combinations. Quercetin + bromelain improves quercetin absorption and anti-inflammatory synergy.